StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Remicade (infliximab by Quarter

Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Merck Remicade (infliximab: -27.0% in Q2 2024, down 16.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q2 2024
-27.0%
Period ended Jun 30, 2024
Change on a year earlier
-16.0 pts
-11.0% in Q2 2023
History
26 quarters
Since Q4 2017
Sources
26
Documents cited below

Where the Q2 2024 figure comes from

“|| Remicade | 39 | 35 | 74 | 51 | 48 | 99 | 45 | 43 | 187 | -27 | -20 | -25 | -21”

Source: Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRemicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q2 2024Jun 30, 2024-27.0%-16.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-24.0%-9.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 2023-1.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 2023-8.0%+25.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 2023-11.0%+18.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 2023-15.0%+14.0 ptsForm 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 2022-33.0%-22.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 2022-29.0%-32.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 2022-29.0%-26.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 2021-24.0%-22.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 2021-11.0%+8.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q2 2021Jun 30, 20213.0%+29.0 ptsForm 8-K (tm2123400d1_ex99-1.htm, filed 2021-07-29) ↗
Q1 2021Mar 31, 2021-3.0%+25.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 2020-2.0%+25.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2020Sep 30, 2020-19.0%+6.0 ptsForm 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020-26.0%+11.0 ptsForm 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗

Cite this data

StockData. (2026). Merck Remicade (infliximab (%), quarterly Q4 2017–Q2 2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-remicade-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.